Novel ruthenium and palladium complexes as potential anticancer molecules on SCLC and NSCLC cell lines

Basit Öğe Kaydı
dc.contributor.authorTokgun, Onur
dc.contributor.authorKarakas, Duygu Elma
dc.contributor.authorTan, Semih
dc.contributor.authorKaragur, Ege Riza
dc.contributor.authorInal, Behcet
dc.contributor.authorAkca, Hakan
dc.contributor.authorDurap, Feyyaz
dc.date.accessioned2024-04-24T16:02:31Z
dc.date.available2024-04-24T16:02:31Z
dc.date.issued2020
dc.departmentDicle Üniversitesien_US
dc.description.abstractLung cancer is one of the major causes of cancer-related deaths in the world. Non-small-cell lung cancer (NSCLC) is the most common type of lung cancer, and small-cell lung cancer (SCLC) is the most aggressive subtype of lung cancer. Proper therapies for SCLC have not yet been developed. However, new molecules have been designed and big innovation in treating SCLC has been achieved. Platinum-based antitumor drugs like cisplatin and carboplatin have several disadvantages including side effects, cisplatin-resistant tumors and limited solubility in aqueous media. Thus, two novel chiral aminoalcohol-based bis(phosphinite) ligands containing (eta(6)-p-cymene)-Ru(II)-phosphinite and bis(phosphinite)-Pd(II) complexes were synthesized and evaluated for anticancer activity. In this study, the results showed that complex1has the strongest cytotoxic effects on SCLC and NSCLC cell lines. On the other hand, cisplatin, ruthenium and palladium complexes are capable to induce apoptosis. Especially, complexes1and2can induce apoptosis for both SCLC and NSCLC. When compared to the qRT-PCR and TUNEL results, we obtained a significant correlation between apoptotic index and p21, Bax gene expressions. This work revealed the potential of the synthesized complexes as anticancer agents with cytotoxic and pro-apoptotic activity as leading compounds for further anticancer researches.en_US
dc.identifier.doi10.1007/s11696-020-01129-x
dc.identifier.endpage2892en_US
dc.identifier.issn2585-7290
dc.identifier.issn1336-9075
dc.identifier.issue9en_US
dc.identifier.scopus2-s2.0-85081330981
dc.identifier.scopusqualityQ2
dc.identifier.startpage2883en_US
dc.identifier.urihttps://doi.org/10.1007/s11696-020-01129-x
dc.identifier.urihttps://hdl.handle.net/11468/14825
dc.identifier.volume74en_US
dc.identifier.wosWOS:000540601300014
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.language.isoenen_US
dc.publisherSpringer International Publishing Agen_US
dc.relation.ispartofChemical Papers
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectSclcen_US
dc.subjectNsclcen_US
dc.subjectPhosphiniteen_US
dc.subjectPalladiumen_US
dc.subjectRutheniumen_US
dc.subjectP21en_US
dc.subjectBaxen_US
dc.titleNovel ruthenium and palladium complexes as potential anticancer molecules on SCLC and NSCLC cell linesen_US
dc.titleNovel ruthenium and palladium complexes as potential anticancer molecules on SCLC and NSCLC cell lines
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu